Wanbury Limited
Regd. Office: BSEL Tech Park,
B-Wing, 10th Floor, Sector-30A,
Opp. Vashi Railway Station,
Vashi, Navi Mumbai 400703
Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

November 18, 2026

To BSE Limited PJ. Towers, Dalal Street Mumbai-400 001. **Scrip Code: 524212**	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. **SYMBOL: WANBURY**

Sub.:Disclosure under Regulation 30 of the SEBI LODR, 2015 – Investors Presentation on Q2 & Half Year ended 30.09.2026

As per Regulation 30 of SEBI LODR, 2015, please find attached herewith copy of Investors Presentation on Un-audited Financial Results (UFR) for the second quarter and half year ended 30th September, 2026 and is also available on the website of the Company at www.wanbury.com

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Limited

JITENDRA JAYANTILAL GANDHI
Digitally signed by JITENDRA JAYANTILAL GANDHI
Date: 2026.11.18 12:14:33 +05'30'

Jitendra J. Gandhi
Company Secretary

Encl.: a/a.

WANBURY

Towards Better Healthcare

Towards Better Healthcare

Earnings Presentation

Q2 & H1FY27 | November 2026

Wanbury Limited

NSE: WANBURY | BSE: 524212
Bloomberg: WANB:IN



Inside this Presentation

Company Profile



Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12

Business Profile



API Business

Strategically Curated Product Portfolio	14
World-Class Manufacturing Infrastructure	15
Developed Market Focused Business Profile	15
Regulatory Approvals	16
Manufacturing Capabilities	17
Strategy & Way Forward	18
Safety First Culture	19



Formulations Business

Re-Building Business	22
Brand Portfolio	23
Strategy & Way Forward	24

Q2 & H1FY27 Earnings Update



Performance Highlights	26
Business Verticals Performance	27
P&L Snapshot	28
Management Commentary	29


Financial Profile



Key Performance Indicators	31
5Y P&L Snapshot	32
5Y Balance Sheet Snapshot	33
5Y Cash Flow Snapshot	34
Capital Markets Overview	35

01 Company Profile

Executive Summary	04
Corporate Journey	05
Successful Business Turnaround	06
Wanbury at a Glance	07
Business Streams	08
Board of Directors	09
Senior Leadership	10
R&D Capabilities	11
Environment, Health & Safety	12



Executive Summary

Successful turnaround to growth momentum

Operational & financial turnaround over last 3 years, now transforming into growth momentum

Global market leaderships in key products

Globally significant market share in Metformin & Sertraline

Building new growth drivers in API business

Through launch of an Anaesthetic in Q4FY26, and pipeline of 4 molecules commercialisation each year beginning current financial year

De-risked & robust balance sheet

Refinanced debt & healthy internal accruals i.e. moderate leverage ratio of ~2X Debt/EBITDA

Established global regulatory approvals



Levers for operating leverage & margin expansion

Through brownfield expansion, operational scale-up, and borrowing cost optimisation

Formulation growth story

Turnaround, break-even (in FY26), to rebuilding & scale-up (in FY27)

Corporate Journey

1990-2000
Foundation & Early Strategic Acquisitions

1990
Incorporated as Pearl Organics Pvt. Ltd.

1992
Established 1st plant for manufacturing APIs

1995
Acquired Brij Chemicals' plant at Patalganga (Maharashtra)

1995
Acquired Wander Limited → a subsidiary of Sandoz (Brand Formulation Business)

1996
Formed a strategic alliance with Wyckoff Chemicals (US) to market APIs in US

2000-2010
Corporate Consolidation & Venture into Developed Markets

2002
USFDA approval received for Patalganga plant

2004
Wander Limited merged with Pearl Organics Limited → Renamed Wanbury Limited

2006
Acquired Doctor's Organic and Chemicals Limited (DOCL) with a multi-purpose USFDA-approved facility in Tanuku

2007
- DOCL merged with Wanbury Limited
- Listing on NSE & BSE
- Acquired Cantabria Pharma S.L. (Spain) - Present in ethical branded formulations in European market

2010-2023
Challenges & Business Turnaround

Underwent Corporate Debt Restructuring with Banks

2020
Deleveraged through strategic sale of brands to Cipla worth ₹87 crore

2021
Capital infusion of ₹50 crore through Preferential Issue

2023
- Raised ₹95 crore via NCD from Neo AIF
- Settlement with all the lenders

2024-Onwards
Transformation & Growth

2024
Scale up EBITDA to ₹73 crore

2025
- Modernised the facilities with an investment of ₹48 crore
- 6th successful USFDA inspection for Patalganga plant (zero 483 observations)
- Successful ANVISA audit clearance for Tanuku plant
- Refinanced Neo AIF Debt at lower interest rate

2026
- Achieved highest-ever Operational EBITDA of ₹108 crore
- *Received nine 'No DMF Deficiency' letters from the USFDA*

Successful Business Turnaround

Financial Turnaround

Debt reduction: ~**75% reduction from peak-debt obligation of ~700 Crores**, including corporate guarantee from Wanbury Limited to Wanbury Holding B.V. (Netherland) for foreign debt held by Netherlands subsidiary

Debt refinancing: **Reduction in borrowing cost from 22.5% to 12.5% with effected from 1st March 2025**, with scope for further reduction in coming years

Exited all high cost private financial agreements

Operational Turnaround

Capacity ramp-up in key existing API products through de-bottlenecking: Metformin (25% increase in last 3 years) & Sertraline (20% increase in last 3 years)

Operational profitability: ~**4X EBITDA scale-up between FY23-FY26,** through de-bottlenecking projects & production scale-up, efficient procurement practises, technical savings, among others

Envisaged break-even profitability in Formulations business, delivered financial break-even in FY26

Wanbury at a Glance

6 products, 100% chronic portfolio
API Portfolio

10+ brands, acute & semi-chronic
Formulations Portfolio

2 USFDA approved API facilities
with 386 KL cumulative reactor capacity

80%+
Export top line, with emphasis on developed markets


1,200+
Employee strength

37+ years
Operating history

Regulatory Approvals

US FDA · EUROPE EDQM · BRAZIL ANVISA · KOREA KDCA · INDIA · MEXICO Cofepris · CANADA · CHINA · WHO GMP

Dual revenue-stream





Business Streams

API


API manufacturer building a niche, profitable & sustainable business (50%+ Gross contribution margins)

Diversified business stream across 6 products + additional launches in pipeline

Regulatory markets focused (EU, Brazil, US) mature & sustainable API business

₹574 Crore
FY26 Revenue

₹309 Crore
H1FY27 Revenue



Formulations

Rebuilding legacy brand formulations business in India

10+ active brands + additional launches in pipeline

Key therapeutic categories such as Anti cold & cough, Anti-infective, Anti-inflammatory, Supplements, Orthopaedic, among others

₹76 Crore
FY26 Revenue

₹39 Crore
H1FY27 Revenue

Board of Directors



Mr. Mohan Kumar Rayana

Promoter & Whole Time Director

25+ years of experience

He holds a Bachelor of Pharmacy from the University of Mumbai and brings over 25 years of diverse experience in the pharmaceutical industry. He has led the company's growth since inception, overseeing strategic acquisitions and operational expansion.



Mr. K. Chandran

Whole Time Director

30+ years of experience

He graduated with a Bachelor of Science from the University of Mumbai and has over 28 years of pharmaceutical sector experience. Mr. Chandran has played a key role in the company's strategic direction and has been associated with Wanbury for more than 25 years.



Dr. Anupama Vaidya

Non Executive Independent Woman Director

30+ years of experience

She holds a Bachelor's degree in Computer Science from the University of Pune as well as an MBA specializing in Human Resource Development from Symbiosis Institute of Business Management, Pune. She brings a strong background in technology and HR development to the board.



Mr. Mridul Mehta

Non Executive Independent Director

30+ years of experience

He holds a BE in Computer Science from Maharaja Sayajirao University Baroda and an MBA in Finance from the Indian Institute of Management (IIM), Bangalore. With more than 30 years of professional experience, Mr. Mehta specializes in business strategy, management consulting, investment banking, and finance.



Mr. Manoj Gursahani

Non Executive Independent Director

35+ years of experience

He serves as the Executive Director of the Mumbai–Global Chamber and is Co-Founder of Vera Healthcare Technologies, an AI-driven platform for early screening and detection of Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration. He brings significant leadership experience from the healthcare and technology sectors.



Mr. Pallavur Sankar Das

Non Executive Independent Director

35+ years of experience

He is an accomplished leader with more than 35 years of experience in the pharmaceutical industry. He has built and scaled businesses across India and other emerging markets. From 2014 to 2022, he was CEO and Director of Curatio Healthcare Private Limited, a domestic dermatology and cosmetic pharmaceutical company.

R&D Capabilities

API R&D Center



Location
Tanuku, Andhra Pradesh

DSIR and FDA (India)
Recognized

R&D Competencies

- New API development
- Cost optimization for existing molecules
- Troubleshooting plant problems
- Analytical development
- Process optimization
- Backward integration development

Immediate Focus Areas:

- Sertraline backward integration
- Metformin yield improvement
- New molecule commercialization's (4 annually)
- Patented molecules process development (post-FY29 focus area)

Formulations R&D Center



Location
Navi Mumbai, Maharashtra

DSIR and FDA (India)
Recognized

R&D Competencies

- Cost optimizations
- New product development
- Process technology development
- Development of Novel Platforms for Speciality Generics and Intellectual Property Rights (IPR)

R&D Capabilities

Process Optimization:
Optimization of synthesis routes for enhanced yields & lowering costs

Impurity Control:
Advanced analytical techniques aligned with ICH guidelines

Analytical Excellence:
DSIR-approved R&D facility with validated methods

Green Chemistry:
Integration of sustainable solvents, catalysis, and waste reduction efforts

Scale-Up Capability:
Lab to commercial with FTE team, integrated QC lab

Environment, Health & Safety

EHS at Wanbury

- **Best-in-class standards:** Committed to global EHS norms and strict regulatory compliance across all operations
- **Environmental focus:** Zero liquid discharge (ZLD) plants, advanced Effluent Treatment Plants (ETP), and continual investment in energy efficiency
- **Sustainable energy:** Upcoming 1.5 MW solar energy project at Satara, to meet 70% of Patalganga site's energy requirements captively through renewable energy
- **Safety culture:** Comprehensive training, systematic risk assessments (HAZOP), and robust emergency response systems at all sites
- **Community & workforce:** Prioritizing safety, public health, and sustainability for employees and local communities





02

Business Profile: API

Strategically Curated Product Portfolio	13
World-Class Manufacturing Infrastructure	14
Developed Market Focused Business Profile	15
Regulatory Approvals	16
Manufacturing Capabilities	17
Strategy & Way Forward	18
Safety First Culture	19



API: Strategically Curated Product Portfolio

Significant global market share in Top 3 products

Molecule	Therapeutic Category	Global Market (MT)	Estimated Market Share
Metformin	Antidiabetic	~75,000	~10%
Sertraline	Antidepressant	~680	~30%
Tramadol	Pain Management	~550	~11%

Existing portfolio – 6 molecules


- Metformin - Antidiabetic
- Sertraline - Antidepressant
- Tramadol - Pain Management
- Paroxetine - Antidepressant
- Mefenamic acid - Anti-inflammatory
- Diphenhydramine - Antihistamine

Recent portfolio addition – 1 molecule


- An Anaesthetic - Commercialised in Q4FY26
- 4 new additions each year beginning FY27

Note - Market Size, Market Share data as per Clarivate & Company Estimates

API - Revenue & Share



API Sales Breakdown



API: World-Class Manufacturing Infrastructure



Site 1: Tanuku, Andhra Pradesh

400 KL
Reactor Capacity

~70%
Revenue Contribution

450+
Headcount

18 Acres
Land Bank

Multi-Purpose Plant

Metformin, Sertraline, Tramadol, Paroxetine, MefenamicAcid, Diphenhydramine, (*upcoming anaesthetic*)

Potential for future brownfield CAPEX



Site 2: Patalganga, Maharashtra

96 KL
Reactor Capacity

~30%
Revenue Contribution

250+
Headcount

2.3 Acres
Land Bank

Dedicated Plant

Metformin, Metformin DC

Fully-occupied at present

Cumulative installed reactor capacity:

500 KL

Future reactor capacity potential at existing sites:

600 KL


API: Developed Market Focused Business Profile


Focused on regulated markets

Exporting to **50+** countries

Exporting to **4+** continents

Total Revenue Mix





Map not to scale, only for illustration purpose.

API: Regulatory Credentials For Both Sites

US – FDA
Approval since **2000**

Last inspection **2024**

Europe – EDQM
Approval since **2007**

Last inspection **2014**

Brazil – ANVISA
Approval since **2024**

Last inspection **2024**

South Korea – KFDA
Approval since **2012**

Last inspection **2026**

Mexico – COFEPRIS
Approval since **2013**

Last inspection **2013**

WHO GMP
Approval since **2007**

Last inspection **2025**

EU Written confirmation
Approval since **2013**

Last inspection **2025**

- **DMF/CEP Filings with Global Regulatory Authorities.**
- Planned filings **Quetiapine Fumarate (US & CEP), Ketamine HCl (CEP) & Paroxetine HCl (Brazil, Korea)**

	Approved	Pending	Total
USA	21	-	21
Europe	8	1	9
Brazil	1	5	6
South Korea	3	-	3
Mexico	-	-	-
ROW	31	-	31
Total			70

API: Manufacturing Capabilities



Chemistry Capabilities

- Azidation
- Bromination
- Cyanation
- Chiral Chemistry
- Optical Resolution
- Demethylation
- Grignard Reaction
- Sodium Metal Reactions
- Metal Hydride Reductions
- Friedel-Crafts Reactions
- Nitration
- Reductions
- Hydrogenation



Reaction Capabilities

- High Pressure Reactions
- High Vacuum Distillations
- Direct Compression (DC) Grade
- Manufacturing Different Polymorphisms
- Hydrated Molecules
- Handling Hygroscopic Products




System Capabilities

- Deployed SAP S4 HANA
- Dedicated software for Sales & Distribution functions
- Dedicated software for Fleet-on-Street
- Dedicated platforms used for sourcing & procurements
- Dedicated solutions for QC management
- Implemented Go-Comet Platform for shipping and freight management

API: Strategy & Way Forward

Way Forward

- Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules
- 4 commercial launches of new molecules each year beginning FY27
- Focus on a mix of:
  a) High-value or
  b) Large-volume + sizable market share molecules
- Target patented molecules supply chain beyond FY29-30
- Deploy backward integration selectively to optimize inputs cost & improve contribution margins



Product Selection Framework

Mid-Size Molecules

Small-to-Mid size molecules + Aim double-digit market share

Client Fit

Favour APIs requested by current marquee clientele

Margin Profile

Aim for ~50% gross margins

API: Safety First Culture





03

Business Profile: Formulations

Re-Building Business	21
Brand Portfolio	22
Strategy & Way Forward	23



Formulations: Re-Building Business

Overview

- Formulations business journey commenced in 1995 with the acquisition of Wander Ltd, formerly a division of Sandoz
- Current portfolio is focused on therapeutics such as anti-cold & cough, anti-infective, anti-inflammatory, analgesic, antipyretic, orthopaedic and constipation medications, as well as protein supplements, multivitamins, and multimineral supplements
- Operating through a fully outsourced manufacturing model, enabling enhanced scalability and flexibility
- Strategic emphasis remains on building strong brands & distribution channels, driven by a dedicated business excellence team



10+
Brands

100%
Acute Therapy


300+
Field Force

30,000+
Doctors Engaged


17
C&F Agents

1,800+
Distributors

Formulations - Revenue & Share



Revenue Mix – Top Brands



Formulations: Brand Portfolio

Top brands

Coriminic®

Anti Cold & Cough



Chymonac™

Pain & Inflammation, Muscular Spasm



RabiPlus™

Antacids & Anti-ulcerants



Senasof™

Herbal Laxative



Nurture®

Protein Supplement



ADTROL

Calcium Supplement - Osteoporosis & Bone Health



WANBURY C RED

Nutritional Supplement



Zeva™

Multivitamin Supplement



Formulations: Strategy & Way Forward

Operational Objectives

1 Latest brand launch (FY25)

C RED (Iron Supplement)

2 Upcoming therapeutic launches

Paediatrics, Dermatology: Better right-to-win through existing brand equity with Paediatricians

Cardiology & Diabetes: Launching chronic & speciality products to improve productivity & add portfolio diversity

Speciality Segments: Building presence across GYN/PED/CP/ORTHO/SUR segments

3 Planned geographic expansion

Expansion into newer attractive regions

Increasing field force for existing regions


Strategic Way Forward

- Leverage 3+ decades of heritage to re-build a scalable branded formulations franchise
- Transition portfolio from acute therapeutics towards speciality and chronic segments through new launches
- Geographical expansion in newer attractive markets
- Achieve profitability break-even in FY26 through better scale & cost-management efforts
- Deliver sustainable profitability FY27 onwards, through: Scaling top brands, launching new therapies, increasing front-line doctor engagement

04

Q2 & H1FY27 Earnings Update

Performance Highlights	25
Business Vertical Performance	26
P&L Snapshot	27
Management Commentary	28







Q2 & H1FY27 Performance Highlights

Revenue (in ₹ Crore)

14%
YOY GROWTH




8%
YOY GROWTH




EBITDA (in ₹ Crore)

1%
YOY GROWTH




(16%)
YOY GROWTH




PAT (in ₹ Crore)

(22%)
YOY GROWTH



(47%)
YOY GROWTH




Business Vertical Performance

API - Revenue (in ₹ Crore)


16%

YOY GROWTH



9%


YOY GROWTH



Formulations - Revenue (in ₹ Crore)


5%

YOY GROWTH



4%

YOY GROWTH



Q2 & H1FY27 P&L Snapshot

PARTICULARS (in ₹ Crore)	Q2FY26	Q1FY27	Q2FY27	YOY Change	QOQ Change	H1FY26	H1FY27	YOY Change
Revenue from Operations	**160.06**	**165.58**	**182.91**	**14%**	**10%**	**323.24**	**348.49**	**8%**
Other Income	0.20	0.36	0.12	-40%	-66%	0.55	0.48	-13%
COGS	67.06	79.00	83.93	25%	6%	142.40	162.93	14%
Gross Profit	**93.20**	**86.95**	**99.10**	**6%**	**14%**	**181.39**	**186.05**	**3%**
Gross Margin (%)	**58.23%**	**52.51%**	**54.18%**	**-405 BPS**	**167 BPS**	**56.12%**	**53.39%**	**-273 BPS**
Operating Expenses	67.22	70.35	72.89	8%	4%	130.62	143.24	10%
EBITDA	**25.98**	**16.60**	**26.21**	**1%**	**58%**	**50.77**	**42.81**	**-16%**
EBITDA Margin (%)	**16.23%**	**10.02%**	**14.33%**	**-190 BPS**	**431 BPS**	**15.71%**	**12.28%**	**-342 BPS**
Finance Cost	7.12	7.97	6.30	-12%	-21%	14.66	14.27	-3%
Depreciation	3.70	4.04	4.19	13%	4%	7.35	8.23	12%
Profit before Tax	**15.16**	**4.59**	**15.72**	**4%**	**243%**	**28.77**	**20.30**	**-29%**
Profit after Tax	**15.18**	**3.24**	**11.88**	**-22%**	**266%**	**28.67**	**15.13**	**-47%**
PAT Margins (%)	**9.48%**	**1.96%**	**6.50%**	**-299 BPS**	**454 BPS**	**8.87%**	**4.34%**	**-453 BPS**
Basic EPS (in ₹)	**4.58**	**0.93**	**3.40**	**-26%**	**266%**	**8.70**	**4.33**	**-50%**

Management Commentary



Mr. Mohan Kumar Rayana
Promoter & Whole Time Director

"Q2 FY27 marks a recovery from the disruption caused by the West Asia crisis in the previous quarter. Revenue from Operations grew 10.5% sequentially and 14.3% year on year, EBITDA margin improved to 14.3% from 10.0% in Q1 FY27, and PAT rose to Rs. 11.9 crore from Rs. 3.2 crore.

Prices of solvents and other crude oil linked raw materials remained elevated through the quarter in the aftermath of the crisis. We have passed on a substantial part of this increase to our customers during the quarter, which is reflected in the sequential improvement in gross margin, and the balance will be passed on in the coming quarter. Margins and profitability on a year-on-year basis still carry the lingering effect of higher input costs, and we expect them to recover fully as the pass-through completes.

Finance costs have reduced following the refinancing of our borrowings at a lower interest rate, and this benefit will continue in the coming quarters.

On the operational front, we received nine 'No DMF Deficiency' letters from the USFDA for Metformin HCl along with similar letters for Paroxetine HCl and Diphenhydramine HCl, a CEP for Rivaroxaban API from EDQM, and the TGA GMP compliance certificate for our Tanuku site. We added new Metformin business in Saudi Arabia and Mexico, and launched our berrysoft™ baby range through Wanbury Skin Health Limited, marking our entry into paediatric dermatology.


On new API product launches, we expect progress towards the end of the current financial year, which will reflect in our performance in the coming year. We continue to work actively on product commercialisation by strengthening the pipeline of products under evaluation.

We expect a better performance on both the topline and profitability fronts in the second half of the year, driven by complete recovery of margins within the existing portfolio and commercialisation of newer products."

05

Financial Profile


Key Performance Indicators	32
5Y P&L Snapshot	33
5Y Balance Sheet Snapshot	34
5Y Cash Flow Snapshot	35
Capital Markets Overview	36






Key Performance Indicators


Revenue from Operations (in ₹ Crore)




Gross Profit & Gross Margins (in ₹ Crore & in %)




EBITDA & EBITDA Margins (in ₹ Crore & in %)




PAT & PAT Margins (in ₹ Crore & in %)




Working Capital Days (in Days)



ROCE (in %)



ROE (in %)



5Y P&L Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	511.2	499.7	575.7	599.51	650.26
Other Income	1.51	0.91	2.99	3.49	0.94
COGS	300.3	303.4	302.6	294.47	276.51
Gross Profit	**212.4**	**197.1**	**276**	**308.53**	**374.70**
Gross Margin (%)	42%	39%	48%	51%	58%
Operating Expenses	175.6	173	203	228.73	267.00
EBITDA	**36.84**	**24.09**	**72.99**	**79.81**	**107.69**
EBITDA Margin (%)	***7%***	***5%***	***13%***	***13%***	***17%***
Finance Cost	20.61	21.4	29.18	36.95	29.98
Depreciation	11.45	12.38	13.03	13.31	14.31
Exceptional Item	76.37	-0.6	-	-	3.60
Profit before Tax	**81.13**	**-9.69**	**30.78**	**29.55**	**59.80**
Profit after Tax	**81.47**	**-10.4**	**30.4**	**30.53**	**66.13**
PAT Margins (%)	***16%***	***-2%***	***5%***	***5%***	***10%***
Basic EPS (in ₹)	**25.29**	**-3.18**	**9.29**	**9.32**	**20.55**

5Y Balance Sheet Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Equity Share Capital					
Equity Share Capital	32.67	32.7	32.74	32.77	34.94
Other Equity	-30.48	-39.96	-4.8	26.5	109.51
Non-Current Liabilities					
Long Term Borrowings	-	-	82	160.29	147.15
Others	16.2	16.31	19.45	19.74	25.03
Current Liabilities					
Short Term Borrowings	67.02	64.14	27.27	12.94	68.30
Trade Payables	191.1	148.2	162.8	138.46	107.25
Advances from customers	14.92	9.27	2.78	2.97	0.01
Others	59.54	71.58	20.93	20.25	25.48
Total Equity and Liabilities	**351**	**302.2**	**343.1**	**413.92**	**517.67**
Non-Current Assets					
Tangible Assets	148.7	151.5	149	189.69	210.26
CWIP	2.35	1.61	3	5.38	25.42
Others	30.24	28.59	32.19	25.4	40.71
Current Assets					
Inventories	49.73	21.99	36.02	37.68	50.63
Trade Receivables	62.8	68.98	89.44	114.16	143.27
Current Investments	-	-	-	-	-
Cash & Bank Balances	25.27	3.89	5.9	12.83	7.63
Others	31.9	25.68	27.55	28.78	37.03
Total Assets	**351**	**302.2**	**343.1**	**413.92**	**517.67**


5Y Cash Flow Snapshot

PARTICULARS (in ₹ Crore)	FY22	FY23	FY24	FY25	FY26
Cash Flow from Operating Activities	37.56	19.8	4.02	26.1	31.53
Cash Flow from Investing Activities	0.59	-8.84	-16.62	-51.17	-56.40
Cash Flow from Financing Activities	-25.62	-31.99	14.55	25.73	22.42
Net Cash Flows	**12.53**	**-21.03**	**1.95**	**0.66**	**-2.45**
Cash at the Beginning of Year	9.96	22.49	1.45	3.4	4.06
Cash at the End of Year	**22.49**	**1.46**	**3.4**	**4.06**	**1.61**

Capital Markets Overview

Shareholding Pattern

(%)



Shareholding data as of 30th September 2026

Current Market Price	**₹200**
52 Week High/Low	**₹359 / ₹162**
Market Capitalization	₹699 Crore
No. of Shares Outstanding	3.50 Crore
NSE	**WANBURY**
BSE	**524212**

Market price data as of 12th November 2026

Get in Touch

This document which has been prepared by Wanbury Limited ("Wanbury" or "the Company"), has been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.

Certain matters discussed in this Document may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world- wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

WANBURY
Towards Better Healthcare

Wanbury Limited

Vinod Verma
Chief Financial Officer
investor@wanbury.com / investorrelations@wanbury.com

Jitendra J Gandhi
Company Secretory
cs@wanbury.com

TIL Advisors Private Limited

Sayam Pokharna
Investor Relations Advisor
sayam@theinvestmentlab.in

Adfactors PR

Hanishi Shah / Smit Shah
Investor Relations Advisor
Hanishi.shah@adfactorspr.com / smit.shah@adfactorspr.com